Monopar Phase 3 data show persistent disease burden in treated Wilson disease patients
MNPR•Monopar Therapeutics presented Phase 3 FoCus baseline findings and ALXN1840 safety data at AASLD’s The Liver Meeting 2026, held Nov. 5-9. Baseline findings showed residual disease burden despite long-term standard treatment; ALXN1840 showed no molybdenum toxicity, with uric acid remaining normal over six years.
1. Meeting findings
Monopar Therapeutics presented Phase 3 FoCus baseline findings and ALXN1840 safety data at AASLD’s The Liver Meeting 2026, held Nov. 5-9. The baseline findings showed substantial residual Wilson disease burden despite long-term standard treatment.
2. Safety data
The investigational therapy ALXN1840 showed no molybdenum toxicity, while uric acid remained normal over six years.
